HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Results for CTL/CD8+ T-Cell Epitope Variants

Filter results by Mutation Type:

LLNATAIAVAEGTDRVIE gp160(814-831) human epitope
      IAVAEGTDRVIEVVQRACRA gp160(820-839) human epitope
        VAEGTDRVIEI gp160(822-832) human epitope
        VAEGTDRVIEELQRA gp160(822-836) human epitope
        VAEGTgRVIEgLQRA gp160(822-836) observed variant
        VAEGTDRVIEgLQRA gp160(822-836) observed variant
        VAEGTDRVIEEsQRA gp160(822-836) observed variant
        VAEGTDRiIEEsQRA gp160(822-836) observed variant
        VAEGTDRVIEaLQRA gp160(822-836) observed variant
        {t}VAEGTDRVIEELQRA gp160(822-836) compensatory mutation; inferred escape; processing
        {t}VAEGTDRVIEgLQRA gp160(822-836) compensatory mutation; inferred escape; processing
        {t}VAEGTDRiIEgLQRA gp160(822-836) compensatory mutation; inferred escape; processing
        {v}VAEGTDRiIEgLQRv gp160(822-836) compensatory mutation; inferred escape; processing
        {v}VAEGTDRiIEgLQRA gp160(822-836) compensatory mutation; inferred escape; processing
          EGTDRIVIEI gp160(824-832) human epitope
          EATDRILEL gp160(824-832) human epitope
            TDRVIEVGQRLGRAI gp160(826-840) A*33:03 human epitope
            TDRVIEVaQRayRAI gp160(826-840) subtype-specific susceptible form
             DRVIEELQR gp160(827-835) human epitope
             DRVIEVVQGAYRAIR gp160(827-841) A2 human epitope
             DRVIEVVQGAYRAIR gp160(827-841) H-2d, H-2p, H-2q, H-2u mouse epitope
             DRVIEVVQGAYRAIR gp160(827-841) H-2d, H-2p, H-2q, H-2u mouse epitope
             DRVIEVVQGAYRAIR gp160(827-841) mouse epitope
             DRVIEVVQGAYRAIR gp160(827-841) human epitope
              KVIEVAQGA gp160(828-836) A*02 human epitope
              RVIEVAQRV gp160(828-836) A*02:01 human epitope
              RVIkVvQRV gp160(828-836) diminished response
              RVIEVLQRA gp160(828-836) A*02:01 human epitope
              RVIEVLQRA gp160(828-836) A*02:01 human epitope
              RVIEVLQAAYR gp160(828-838) A*11:01 human epitope
               VIEVVQRACRAILHI gp160(829-843) mouse epitope
                IEVVQRACRAILHIPRRI gp160(830-847) human epitope
                IEVVQRACRAILHIPRkI gp160(830-847) observed variant
                IEiVQRACRAILHIPRRI gp160(830-847) observed variant
                IEVVQRACRAIcHIPRRI gp160(830-847) observed variant
                IEVVQRACRAIrHIPRRI gp160(830-847) observed variant
                IEVVQRACRAILHIPRRI gp160(830-847) human epitope
                IEVVQRACRAIfHIPRRI gp160(830-847) observed variant
                IEiVQRACRAILHIPRRI gp160(830-847) observed variant
                IEVVQRACRAILHIPRkI gp160(830-847) observed variant
                IEVVQRACRAIcHIPRRI gp160(830-847) observed variant
                IEVVQRACRAIrHIPRRI gp160(830-847) observed variant
                IEVVQRACRAILHIPRRIRQ gp160(830-849) human epitope
                IEVVQGAYRAIIRHIPRRIRQGLERI gp160(830-854) human epitope
                 EVAQRAYR gp160(831-838) A*29 human epitope
                 EVAQRAYR gp160(831-838) A*33:03 human epitope
                 EVAQRAYR gp160(831-838) A*33:03 human epitope
                 EVAQRAYR gp160(831-838) B*08 human epitope
                 EVVQRAYR gp160(831-838) human epitope
                 EVaQRAYR gp160(831-838) observed variant
                   VQRTCRAIL gp160(833-841) human epitope
                   LQRAGRAILHIPTRI gp160(833-847) human epitope
                     RAYRAILHI gp160(835-843) B51 human epitope
                     RtfRAILHI gp160(835-843) observed variant
                     RiYRAILHx gp160(835-843) observed variant
                     RAYRAILHI gp160(835-843) B*51:01 human epitope
                     RACRAILHI gp160(835-843) human epitope
                      IGRAILHIPR gp160(836-845) B*27:05 human epitope
                       CRAILHIPR gp160(837-845) B*27:02 human epitope
                       CRAILHIPR gp160(837-845) B*27:05 human epitope
                       YRAIRHIPRRIRQGLERILL gp160(837-856) A30, B35 human epitope
                       YRAIRHIPRRIRQGLERILL gp160(837-856) B8 human epitope
                       YRAIRHIPRRIRQGLERILL gp160(837-856) human epitope
                       YRAIRHIPRRIRQGLERILL gp160(837-856) human epitope
                       CRAILHIPRRIRQGLERALL gp160(837-856) human epitope
                       RAILHIPRRIRQGLERsL gp160(837-856) observed variant
                       RAILHIPtRIRQGLERcL gp160(837-856) observed variant
                        RAIYSIPRR gp160(838-846) human epitope
                        RAILHIPRRIRQGLERAL gp160(838-855) human epitope
                        RAVLNIPTRIRQGLERAL gp160(838-855) human epitope
                        RAVLNvPTRIRQGLERAL gp160(838-855) observed variant
                        RAILHIPRRIRQGLERSL gp160(838-855) human epitope
                        RAILHIPtRIRQGLERcL gp160(838-855) observed variant
                        CRAILHIPRRIRQGLERALL gp160(838-855) observed variant
                        RAILHIPTRIRQGLERCL gp160(838-855) human epitope
                        CRAILHIPrRIRQGLERaLL gp160(838-855) observed variant
                        RAILHIPrRIRQGLERsL gp160(838-855) observed variant
                          ILHIPRRIRQGLERA gp160(840-854) human epitope
                           RNIPIRIRQ gp160(841-849) human epitope
                           LNIPRRIRQGLERAL gp160(841-855) B*07:02 human epitope
                           LHIPTRIRQGLERAL gp160(841-855) human epitope
                            HIPRRIRQGLERALL gp160(842-856) human epitope
                            HIPRRIRQGLERALL gp160(842-856) human epitope
                             IPRRIRQGL gp160(843-851) A*02:01 human epitope
                             IPRRIRQGL gp160(843-851) A*29 human epitope
                             IPRRIRQGL gp160(843-851) B*07 human, transgenic mouse epitope
                             IPRRIRQGf gp160(843-851) susceptible form
                             IPRRIRQGL gp160(843-851) B*07 human epitope
                             IPRRRIRQGL gp160(843-851) B*07 human epitope
                             IPRRIRQGL gp160(843-851) B*07 human epitope
                             IPRRIRQGF gp160(843-851) B*07 human epitope
                             IPRRIRQGL gp160(843-851) B*07 human epitope
                             IPRRIRQGL gp160(843-851) B*07 human epitope
                             IPRRIRQGL gp160(843-851) B*07:02 human epitope
                             IPRRIRQGL gp160(843-851) B*07:02 human epitope
                             IPtRIRQGL gp160(843-851) literature escape
                             IPRRIRQGL gp160(843-851) B*07:02 human epitope
                             IPRRIRQGf gp160(843-851) subtype-specific susceptible form
                             IPRRIRQGL gp160(843-851) B*07:02 human epitope
                             IPRRIRQGL gp160(843-851) B*07:02 human epitope
                             IPRRIRQGL gp160(843-851) B*41 human epitope
                             IPRRIRQGF gp160(843-851) B*42 human epitope
                             lPRRIRQGF gp160(843-851) observed variant
                             IPRRvRQGF gp160(843-851) observed variant
                             IPRRlRQGF gp160(843-851) observed variant
                             IPRRfRQGF gp160(843-851) observed variant
                             IPtRIRQGF gp160(843-851) observed variant
                             IPRRIRQGF gp160(843-851) B*42:01 human epitope
                             IPRRIRQGF gp160(843-851) B*42:01 human epitope
                             IPRRIRQGF gp160(843-851) B*42:01 human epitope
                             vPRRIRQGF gp160(843-851) escape documented in this paper; observed variant
                             IPtRIRQGF gp160(843-851) escape documented in this paper; observed variant
                             IPRRIRQGL gp160(843-851) B*42:01 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGf gp160(843-851) subtype-specific susceptible form
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             vPRRIRQGL gp160(843-851) observed variant
                             IPgRIRQGL gp160(843-851) observed variant
                             IPRRkRQGL gp160(843-851) observed variant
                             IPRRIRQGf gp160(843-851) observed variant
                             IPRRIRQGL gp160(843-851) B7 epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGF gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGf gp160(843-851) calculated diminished HLA binding; observed variant
                             IPtRIRQGL gp160(843-851) calculated diminished HLA binding; observed variant
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQdL gp160(843-851) non-susceptible form
                             IPtRIRQGL gp160(843-851) diminished response
                             IPRRlRQGL gp160(843-851) diminished response
                             IPtRIRQGf gp160(843-851) non-susceptible form
                             IPRRIRQGL gp160(843-851) B7 human epitope
                             IPRRIRQGL gp160(843-851) B*81 human epitope
                             IPRRIRQGL gp160(843-851) C*05 human epitope
                             IPRRIRQGA gp160(843-851) human epitope
                             IPRRIRQGL gp160(843-851) human epitope
                             IPRRIRQGf gp160(843-851) subtype-specific susceptible form
                             IPTRIRQGL gp160(843-851) human epitope
                             IPrRIRQGL gp160(843-851) observed variant
                             IPRRIRQGF gp160(843-851) human epitope
                             IPRRIRQGA gp160(843-851) human epitope
                             IPRRIRQGF gp160(843-851) human epitope
                             IPRRIRQGL gp160(843-851) human epitope
                             IPRRIRQGL gp160(843-851) human epitope
                             IPRRIRQGf gp160(843-851) subtype-specific susceptible form
                             IvRRIRQGL gp160(843-851) subtype-specific susceptible form
                             IPRRIRQGF gp160(843-851) human epitope
                             IPRRIRQGL gp160(843-851) human epitope
                             IPRRIRQGL gp160(843-851) human epitope
                             IPRRIRQGLA gp160(843-852) B*07:02 human epitope
                               RRIRQGLERILL gp160(845-856) A30, B8 human epitope
                               RRIRQGLERILL gp160(845-856) B7, B8 human epitope
                               RRIRQGLERILL gp160(845-856) human epitope
                                RIRQGLERA gp160(846-854) A*02:05 human epitope
                                RIRQGLERA gp160(846-854) A*02:05 human epitope
                                RIRQGfERA gp160(846-854) observed variant
                                RIRQGLEaA gp160(846-854) observed variant
                                RIRQGfEaA gp160(846-854) observed variant
                                RIRQGLfRA gp160(846-854) observed variant
                                RIRQGLERA gp160(846-854) A*02:05 human epitope
                                RIRQGLERA gp160(846-854) A*02:05 human epitope
                                RIRQGLERA gp160(846-854) A2 human epitope
                                RIRQGLERA gp160(846-854) A2 human epitope
                                RIRQGLERA gp160(846-854) human epitope
                                RIRQGLERALL gp160(846-856) human epitope
                                 IRQGLERAL gp160(847-855) B*27:02 human epitope
                                 IRQGLERAL gp160(847-855) B*27:05 human epitope
Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health